AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01190059
Drug: Ex vivo lung perfusion with Steen Solution™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
Trial: NCT01780259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
Trial: NCT02623751
Drug: KHK2375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily.
Trial: NCT01011868
Drug: BI 10773 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 10773 placebo
Trial: NCT01275781
Drug: [14C]-AZD9742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg intravenous over 2 hours
Trial: NCT02649504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
Trial: NCT02879526
Drug: C-CPT
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
Trial: NCT00167206
Drug: Cyclophosphamide, Fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
Trial: NCT01670773
Drug: Salsalate + DHA
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01670773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01316146
Drug: CAR.CD30 T cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2~Group Two, 1x10\^8 cells/m\^2~Group Three, 2x10\^8 cells/m\^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc.
Trial: NCT04816123
Drug: [14C]Donafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each volunteers received a single 300 mg dose of \[14C\]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
Trial: NCT01469520
Drug: Epivir®, Retrovir® and Viramune®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
Trial: NCT03019419
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02570997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered.
Trial: NCT01449955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive
Trial: NCT03010579
Drug: iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
Trial: NCT03008798
Drug: Herbal Medicine C-117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C117 formula including 2 herbals and 2 insects
Trial: NCT03008798
Drug: The Placebo of Herbal Medicine C-117
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03095469
Drug: 0.9%NaCl solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
Trial: NCT00002539
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03548220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching AG-348 tablets, administered to maintain the blind.
Trial: NCT00501657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg mane for 2 days
Trial: NCT00611975
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
Trial: NCT03468790
Drug: CMAB007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the study drug
Trial: NCT03468790
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active components
Trial: NCT04083963
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.
Trial: NCT04083963
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
Trial: NCT00358215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection
Trial: NCT03078569
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment with testosterone gel
Trial: NCT01340248
Drug: Dilatrend 64mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~2. Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting
Trial: NCT01184001
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
Trial: NCT01184001
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
Trial: NCT00143104
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03408405
Drug: Acthar Gel 80 UNT/ML Injectable Solution
RxNorm normalized name: Acthar Gel 80 UNT/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
Trial: NCT01385748
Drug: Placebo Lauriad®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
Trial: NCT00233480
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo Qd x 3 months
Trial: NCT02262611
Drug: Micardis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02262611
Drug: MicardisPlus®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02774811
Drug: Prostaglandin analogue
RxNorm normalized name: Prostaglandin analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy
Trial: NCT00003534
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT04204382
Drug: Compound Kushen Injection（CKI）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKI, 20mL each time, once a day, intravenous drip. Treatment course is 7 days.
Trial: NCT00557557
Drug: Drug: 5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
Trial: NCT03388268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar liquid manufactured to mimic oral vancomycin 125mg
Trial: NCT03507543
Drug: IMP4297
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Trial: NCT00079794
Drug: mistletoe
RxNorm normalized name: MISTLETOE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01681277
Drug: Placebo to BI 113608 PIB bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: powder for oral solution
Trial: NCT02858453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appearance and weight matched placebo tablets
Trial: NCT01200342
Drug: Genasense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
Trial: NCT01475305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
Trial: NCT01475305
Drug: MEDI-557
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
Trial: NCT02385058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet orally once starting on Day 21.
Trial: NCT00557908
Drug: VWF/FVIII products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses
Trial: NCT01516255
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
Trial: NCT01516255
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
Trial: NCT03752177
Drug: LY3415244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00725270
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT02673632
Drug: Merional ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 \< 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
Trial: NCT01423591
Drug: inactive powder
RxNorm normalized name: collagen,activated Topical Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
Trial: NCT02779114
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
Trial: NCT00087776
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00538148
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02248818
Drug: AZD8108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: AZD8108 Single or Multiple doses administered orally as a solution.
Trial: NCT02248818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
Trial: NCT02961855
Drug: anesthesics plus antiinflammatory, CLIFE1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
Trial: NCT04425590
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg tablet once daily
Trial: NCT04425590
Drug: Vit B12
RxNorm normalized name: vit B12/pyridoxine/thiamine ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit B12 100 mg tablet three times daily
Trial: NCT02961855
Drug: local anesthesics, CLIFE2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
Trial: NCT01955187
Drug: CYCLOPHOSPHAMIDE
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
Trial: NCT01986088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00527787
Drug: PN400 (VIMOVO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
Trial: NCT00527787
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg) dosed twice daily (bid) orally
Trial: NCT00218608
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
Trial: NCT02179177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01981005
Drug: RO5424802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses followed by IV or oral administration of a 14C-labeled tracer
Trial: NCT03098563
Drug: Blinded study medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
Trial: NCT04324905
Drug: HIP1802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT04324905
Drug: HGP1705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug
Trial: NCT00964262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plcacebo of each doasage, single subcutanoeus injection
Trial: NCT02484482
Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03748979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-925 Placebo
Trial: NCT00519675
Drug: alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01541852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet twice daily
Trial: NCT02393742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01016262
Drug: MAX-002
RxNorm normalized name: heparinoids 0.002 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
Trial: NCT01016262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
Trial: NCT02132832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Trial: NCT00919191
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel 0.04% used once daily in a split-face model
Trial: NCT00002475
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03733353
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03733353
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01821404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar capsules as in the atorvastatin arm, but without the active ingredient
Trial: NCT00039663
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00441051
Drug: Diclofenac sodium 1mg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03840005
Drug: Ursonorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid
Trial: NCT02979249
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for one year
Trial: NCT00338962
Drug: desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg per day
Trial: NCT00338962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01093443
Drug: ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFSH with GnRH antagonists
Trial: NCT01224977
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin 500 mg 3/week for 3 months
Trial: NCT03815812
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
Trial: NCT00259350
Drug: Skin disinfection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02406261
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg simvastatin will be administered orally as 1 × 20-mg tablet
Trial: NCT00914745
Drug: Ointment
RxNorm normalized name: Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
Trial: NCT00825539
Drug: AQW051
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00825539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01777165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion
Trial: NCT00742105
Drug: BGT226
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00239785
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00154687
Drug: Paclitaxel, Cisplatin, 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01948362
Drug: Sulforadex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active compound
Trial: NCT02463045
Drug: TOP1288
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03335436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery